CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向 BCMA、GPRC5D 或 FcRH5 的 T 细胞衔接器治疗复发/难治性多发性骨髓瘤：CAR-T 细胞疗法之外的格局——系统综述与网络 Meta 分析

T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review

仅仅是触及表面：靶向细胞膜蛋白的多发性骨髓瘤新型治疗方法

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.

多发性骨髓瘤当前的新型靶向治疗策略

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

无限可能以及如何利用它们？最佳治疗顺序是什么？

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

多发性骨髓瘤治疗前线的革命：寻找治愈方法的经验与挑战

Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.

双特异性抗体在多发性骨髓瘤中的进展：新进展与未来方向

Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead.

多发性骨髓瘤细胞治疗的新方法：聚焦 CAR-T 细胞

Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells.

CAR-T 细胞疗法在多发性骨髓瘤治疗中显示出显著获益。

双特异性抗体治疗复发/难治性多发性骨髓瘤：更新与未来展望

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.

用于多发性骨髓瘤的 T 细胞重定向双特异性抗体：变化治疗格局中的新兴治疗策略

T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.